Novel drugs for the treatment of chronic pruritus

References

• Pereira MP, Steinke S, Bruland P, et al. Management of chronic pruritus: from the dermatological office to the specialized itch center. A Rev Itch. 2017;2:e06.
   Google Scholar
• Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291–294.
   PubMed Web of Science ®Google Scholar
• Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci. 2006;7(7):535–547.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Carstens E. Neural processing of itch. Neuroscience. 2013;250:697–714.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563–581.
   PubMed Web of Science ®Google Scholar
• Stander S, Zeidler C, Augustin M, et al. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion. J Dtsch Dermatol Ges. 2017;15(8):860–873.
   Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e494.
   PubMed Web of Science ®Google Scholar
• Misery L, Erfan N, Castela E, et al. Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up. Acta Derm Venereol. 2015;95(7):864–865.
   PubMed Web of Science ®Google Scholar
• Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and management of neuropathic itch. Dermatol Clin. 2018;36(3):213–224.
   PubMed Web of Science ®Google Scholar
• Takamori A, Nambu A. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Sci Rep. 2018;8(1):6639.
   PubMedGoogle Scholar
• Bagci IS, Ruzicka T. IL-31: a new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858–866.
   PubMed Web of Science ®Google Scholar
• Gangemi S, Quartuccio S, Casciaro M, et al. Interleukin 31 and skin diseases: a systematic review. Allergy Asthma Proc. 2017;38(6):401–408.
   PubMed Web of Science ®Google Scholar
• Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421–423.
   PubMed Web of Science ®Google Scholar
• Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized anti-human IL-31 receptor A antibody, for healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomised, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296–304.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121-1130.e7. doi: 10.1016/j.jaci.2018.03.018.
   Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506–515.
   PubMed Web of Science ®Google Scholar
• Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3s1):S43–s52.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, A non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98(5):484–489.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Stein Gold LF, Murrell DF, et al. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies. J Drugs Dermatol. 2016;15(2):172–176.
   PubMed Web of Science ®Google Scholar
• Cheape AC, Murrell DF. 2% crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Rev Clin Immunol. 2017;13(5):415–423.
   PubMed Web of Science ®Google Scholar
• Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147(1):71–79.
   PubMed Web of Science ®Google Scholar
• Takada S, Kou K, Nagashima Y, et al. Aberrant epidermal expression of semaphorin 3A and nerve growth factor in prurigo nodularis. J Dermatol. 2013;40(5):404–406.
   PubMed Web of Science ®Google Scholar
• Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–548.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ganchingco JR, Mishra SK, et al. Janus kinase inhibitors display broad anti-itch properties: A possible link through the TRPV1 receptor. J Allergy Clin Immunol. 2017;140(1):306–309.e303.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228.e213.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE‐052, a janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre randomized, vehicle‐controlled clinical study. Br J Dermatol. 2018;178:424–432.
   PubMed Web of Science ®Google Scholar
• Bushmakin AG, Mamolo C, Cappelleri JC, et al. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26(1):19–22.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Thaci D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(6):1162–1170.e1163.
   PubMed Web of Science ®Google Scholar
• Vaa BE, Tefferi A, Gangat N, et al. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Ann Hematol. 2016;95(7):1185–1189.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–520.
   PubMed Web of Science ®Google Scholar
• Kirito K, Suzuki K, Miyamura K, et al. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. Int J Hematol. 2018;107(2):173–184.
   PubMed Web of Science ®Google Scholar
• Patacchini R, Lecci A, Holzer P, et al. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci. 2004;25(1):1–3.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Armstrong CA, Bunnett NW, et al. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol. 1998;7(2–3):81–96.
   PubMed Web of Science ®Google Scholar
• Liu JY, Zhao YZ, Peng C, et al. [Effect of cetirizine hydrochloride on the expression of substance P receptor and cytokines production in human epidermal keratinocytes and dermal fibroblasts]. Yao Xue Xue Bao. 2008;43(4):383–387.
   PubMedGoogle Scholar
• Li WW, Guo TZ, Liang DY, et al. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012;116(4):882–895.
   PubMed Web of Science ®Google Scholar
• Kawana S, Liang Z, Nagano M, et al. Role of substance P in stress-derived degranulation of dermal mast cells in mice. J Dermatol Sci. 2006;42(1):47–54.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240–1246.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the aprepitant protocol 052 study group. J Clin Oncol. 2003;21(22):4112–4119.
   PubMed Web of Science ®Google Scholar
• Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92(1084):87–98.
   PubMed Web of Science ®Google Scholar
• Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
   PubMed Web of Science ®Google Scholar
• Ally MS, Gamba CS, Peng DH, et al. The use of aprepitant in brachioradial pruritus. JAMA Dermatol. 2013;149(5):627–628.
   PubMed Web of Science ®Google Scholar
• Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361(14):1415–1416.
   PubMed Web of Science ®Google Scholar
• Torres T, Fernandes I, Selores M, et al. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14–15.
   PubMed Web of Science ®Google Scholar
• Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665–667.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Fratto ME, Santini D, et al. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010;18(9):1229–1230.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020–1024.
   PubMed Web of Science ®Google Scholar
• Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(4):397–398.
   PubMed Web of Science ®Google Scholar
• Ohanyan T, Schoepke N, Eirefelt S, et al. Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derm Venereol. 2018;98:26–31.
   PubMed Web of Science ®Google Scholar
• [ cited 2018 July 10]. Available from: https://www.prnewswire.com/news-releases/vandas-tradipitant-improves-itch-and-disease-severity-in-patients-with-atopic-dermatitis-300519177.html
   Google Scholar
• Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680–688.
   PubMed Web of Science ®Google Scholar
• Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol. 2017;46(6):450–458.
   PubMed Web of Science ®Google Scholar
• Hawi A, Alcorn H Jr., Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47.
   PubMed Web of Science ®Google Scholar
• Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16(12):3742–3747.
   PubMed Web of Science ®Google Scholar
• Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25(4):1251–1257.
   PubMed Web of Science ®Google Scholar
• Kumagai H, Ebata T, Takamori K, et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012;36(2):175–183.
   PubMed Web of Science ®Google Scholar
• Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47(10):972–982.
   PubMed Web of Science ®Google Scholar
• Akuta N, Kumada H, Fujiyama S. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride. Hepatol Res. 2018;48(1):45–50.
   Google Scholar
• Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for kappa opioid receptors. Handb Exp Pharmacol. 2015;226:291–314.
   PubMedGoogle Scholar
• [ cited 2018 July 10]. Available from: https://www.prnewswire.com/news-releases/tioga-pharmaceuticals-asimadoline-reduces-nighttime-itching-and-improves-disease-related-quality-of-life-in-patients-with-atopic-dermatitis-300566114.html
   Google Scholar
• [ cited 2018 July 10]. Available from: http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-positive-results-phase-2-trial
   Google Scholar
• Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114–1123.
   PubMed Web of Science ®Google Scholar
• Al-Dury S, Wahlstrom A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8(1):6658.
   PubMedGoogle Scholar
• Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91(6):674–679.
   PubMed Web of Science ®Google Scholar
• Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534.
   PubMed Web of Science ®Google Scholar